Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025
Humacyte (NASDAQ: HUMA), a clinical-stage biotechnology company focused on developing universally implantable, bioengineered human tissue, has scheduled its Q1 2025 financial results release and corporate update for May 13, 2025. The company will host a conference call and webcast at 8:30 AM ET.
U.S. investors can join via 1-877-704-4453, while international participants can dial 1-201-389-0920 using conference ID 13753487. The webcast will be available 15 minutes before the call and remain accessible on the company's investor relations website for at least 30 days afterward.
Humacyte (NASDAQ: HUMA), un'azienda biotecnologica in fase clinica specializzata nello sviluppo di tessuti umani bioingegnerizzati e universalmente impiantabili, ha programmato la pubblicazione dei risultati finanziari del primo trimestre 2025 e un aggiornamento aziendale per il 13 maggio 2025. La società terrà una conference call e una webcast alle 8:30 AM ET.
Gli investitori statunitensi possono partecipare chiamando il numero 1-877-704-4453, mentre i partecipanti internazionali possono utilizzare il numero 1-201-389-0920 con ID conferenza 13753487. La webcast sarà disponibile 15 minuti prima dell'inizio della chiamata e resterà accessibile sul sito web delle relazioni con gli investitori dell'azienda per almeno 30 giorni dopo l'evento.
Humacyte (NASDAQ: HUMA), una empresa biotecnológica en etapa clínica enfocada en el desarrollo de tejidos humanos bioingenierizados e implantables universalmente, ha programado la publicación de sus resultados financieros del primer trimestre de 2025 y una actualización corporativa para el 13 de mayo de 2025. La compañía llevará a cabo una llamada de conferencia y una transmisión en vivo a las 8:30 AM ET.
Los inversores en EE.UU. pueden unirse marcando el 1-877-704-4453, mientras que los participantes internacionales pueden llamar al 1-201-389-0920 con ID de conferencia 13753487. La transmisión estará disponible 15 minutos antes de la llamada y permanecerá accesible en el sitio web de relaciones con inversionistas de la compañía por al menos 30 días después.
Humacyte (NASDAQ: HUMA)는 보편적으로 이식 가능한 생체공학 인체 조직 개발에 주력하는 임상 단계 생명공학 회사로, 2025년 1분기 재무 결과 발표 및 기업 업데이트를 2025년 5월 13일에 예정했습니다. 회사는 동부 시간 오전 8시 30분에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
미국 투자자들은 1-877-704-4453으로 참여할 수 있으며, 국제 참가자는 컨퍼런스 ID 13753487을 사용하여 1-201-389-0920으로 전화할 수 있습니다. 웹캐스트는 콜 시작 15분 전에 제공되며, 행사 후 최소 30일간 회사의 투자자 관계 웹사이트에서 시청할 수 있습니다.
Humacyte (NASDAQ : HUMA), une société biotechnologique en phase clinique spécialisée dans le développement de tissus humains bio-ingénierés universellement implantables, a programmé la publication de ses résultats financiers du premier trimestre 2025 et une mise à jour d'entreprise pour le 13 mai 2025. La société organisera une conférence téléphonique et une webdiffusion à 8h30 (heure de l'Est).
Les investisseurs américains peuvent participer en appelant le 1-877-704-4453, tandis que les participants internationaux peuvent composer le 1-201-389-0920 avec l'ID de conférence 13753487. La webdiffusion sera disponible 15 minutes avant l'appel et restera accessible sur le site des relations investisseurs de la société pendant au moins 30 jours après.
Humacyte (NASDAQ: HUMA), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung universell einsetzbarer, bioengineerter menschlicher Gewebe spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 und ein Unternehmensupdate für den 13. Mai 2025 geplant. Das Unternehmen wird eine Telefonkonferenz und eine Webcast um 8:30 Uhr ET veranstalten.
US-Investoren können über die Nummer 1-877-704-4453 teilnehmen, internationale Teilnehmer wählen die Nummer 1-201-389-0920 mit der Konferenz-ID 13753487. Der Webcast wird 15 Minuten vor Beginn der Telefonkonferenz verfügbar sein und mindestens 30 Tage lang auf der Investor-Relations-Webseite des Unternehmens abrufbar bleiben.
- None.
- None.
DURHAM, N.C., May 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended March 31, 2025, on Tuesday, May 13, 2025. Management will host a webcast and conference call at 8:30 a.m. ET to provide a corporate and financial update.
| Title: | Humacyte First Quarter 2025 Financial Results and Corporate Update |
| Date: | May 13, 2025 |
| Time: | 8:30 AM Eastern Time |
| Conference Call Details: | 1-877-704-4453 (U.S. Investors Dial) 1-201-389-0920 (International Investors Dial) 13753487 (Conference ID) |
| Call meTM Feature: | Click Here |
| Webcast: | Click Here |
The webcast should be accessible 15 minutes prior to the conference call’s start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company’s website for at least 30 days.
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received an RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
FAQ
When will Humacyte (HUMA) release its Q1 2025 earnings?
What time is Humacyte's Q1 2025 earnings call?
How can I join Humacyte's Q1 2025 earnings call?
How long will Humacyte's Q1 2025 earnings call replay be available?
